CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067415
035-os BibID:(WoS)000392425200005 (Scopus)84991585385
Első szerző:Agca, R.
Cím:EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update / R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J. L. Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. Semb, G. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P. M. Symmons, M. T. Nurmohamed
Dátum:2017
ISSN:0003-4967
Megjegyzések:Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 1 (2017), p. 17-28. -
További szerzők:Heslinga, S. C. Rollefstad, S. Heslinga, M. McInnes, I. B. Peters, M. J. L. Kvien, Tore K. Dougados, Maxime Radner, H. Atzeni, F. Primdahl, Jette Södergren, A. Wallberg Jonsson, S. van Rompay, J. Zabalan, C. Pedersen, T. R. Jacobsson, L. de Vlam, K. Gonzalez-Gay, Miguel A. Semb, Anne Grete Kitas, George Smulders, Yvo M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Symmons, D. P. M. Nurmohamed, Michael T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM103789
035-os BibID:(WOS)000859802100001 (Scopus)85139865478
Első szerző:Charles-Schoeman, Christina
Cím:Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease : a post hoc analysis from ORAL Surveillance / Christina Charles-Schoeman, Maya H. Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L. Rivas, Arne Yndestad, Carol A. Connell, Zoltan Szekanecz
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance. Methods Patients with RA aged >= 50 years with >= 1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. Hazard rations (HRs) were evaluated for the overall population and by history of ASCVD (exploratory analysis). Results Risk of MACE, myocardial infarction and sudden cardiac death were increased with tofacitinib versus TNFi in ORAL Surveillance. In patients with history of ASCVD (14.7%; 640/4362), MACE incidence was higher with tofacitinib 5 mg two times per day (8.3%; 17/204) and 10 mg two times per day (7.7%; 17/222) versus TNFi (4.2%; 9/214). HR (combined tofacitinib doses vs TNFi) was 1.98 (95% confidence interval (CI) 0.95 to 4.14; interaction p values: 0.196 (for HR)/0.059 (for incidence rate difference)). In patients without history of ASCVD, MACE HRs for tofacitinib 5 mg two times per day (2.4%; 30/1251) and 10 mg two times per day (2.8%; 34/1234) versus TNFi (2.3%; 28/1237) were, respectively, 1.03 (0.62 to 1.73) and 1.25 (0.76 to 2.07). Conclusions This post hoc analysis observed higher MACE risk with tofacitinib versus TNFi in patients with RA and history of ASCVD. Among patients without history of ASCVD, all with prevalent CV risk factors, MACE risk did not appear different with tofacitinib 5 mg two times per day versus TNFi. Due to the exploratory nature of this analysis and low statistical power, we cannot exclude differential MACE risk for tofacitinib 5 mg two times per day versus TNFi among patients without history of ASCVD, but any absolute risk excess is likely low.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Antirheumatic Agents
Arthritis
Rheumatoid
Cardiovascular Diseases
Therapeutics
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 1 (2022), p. 119-129. -
További szerzők:Buch, Maya H. Dougados, Maxime Bhatt, Deepak L. Giles, Jon T. Ytterberg, Steven R. Koch, Gary G. Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Rivas, Jose L. Yndestad, Arne Connell, Carol A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM067427
035-os BibID:(WoS)000401138800008 (Scopus)85007256365
Első szerző:Combe, Bernard
Cím:2016 update of the EULAR recommendations for the management of early arthritis / Bernard Combe, Robert Landewe, Claire I. Daien, Charlotte Hua, Daniel Aletaha, Jose María Álvaro-Gracia, Margôt Bakkers, Nina Brodin, Gerd R. Burmester, Catalin Codreanu, Richard Conway, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Joao Fonseca, Karim Raza, Lucía Silva-Fernández, Josef S. Smolen, Diana Skingle, Zoltan Szekanecz, Tore K. Kvien, Annette van der Helm-van Mil, Ronald van Vollenhoven
Dátum:2017
ISSN:0003-4967
Megjegyzések:Objectives Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.Methods In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of ♭management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process.Results The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research.Conclusions These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 6 (2017), p. 948-959. -
További szerzők:Landewé, Robert Daien, Claire I. Hua, Charlotte Aletaha, Daniel Álvaro-Gracia, Jose María Bakkers, Margôt Brodin, Nina Burmester, Gerd R. Codreanu, Catalin Conway, Richard Dougados, Maxime Emery, Paul Ferraccioli, Gianfranco Fonseca, João Raza, Karim Silva-Fernández, Lucía Smolen, Josef S. Skingle, Diana Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kvien, Tore K. van der Helm-van Mil, Annette van Vollenhoven, Ronald
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM108307
035-os BibID:(Scopus)85148667393 (WoS)000926215100001
Első szerző:Dougados, Maxime
Cím:Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme / Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, Jon T. Giles, Steven R. Ytterberg, Deepak L. Bhatt, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Carol A. Connell, Arne Yndestad, Jose L. Rivas, Maya H. Buch
Dátum:2023
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 4 (2023), p. 575-577. -
További szerzők:Charles-Schoeman, Christina Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Giles, Jon T. Ytterberg, Steven R. Bhatt, Deepak L. Koch, Gary G. Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Connell, Carol A. Yndestad, Arne Rivas, Jose L. Buch, Maya H.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM096109
035-os BibID:(WOS)000723328800001 (Scopus)85122302204
Első szerző:Nagy György
Cím:EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis / Nagy György, Roodenrijs Nadia M. T., Welsing Paco M. J., Kedves Melinda, Hamar Attila, van der Goes Marlies C., Kent Alison, Bakkers Margot, Pchelnikova Polina, Blaas Etienne, Senolt Ladislav, Szekanecz Zoltan, Choy Ernest H., Dougados Maxime, Jacobs Johannes W. G., Geenen Rinie, Bijlsma Johannes W. J., Zink Angela, Aletaha Daniel, Schoneveld Leonard, van Riel Piet, Dumas Sophie, Prior Yeliz, Nikiphorou Elena, Ferraccioli Gianfranco, Schett Georg, Hyrich Kimme L., Mueller-Ladner Ulf, Buch Maya H., McInnes Iain B., van der Heijde Désirée, van Laar Jacob M.
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objective To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficultto-treat rheumatoid arthritis (D2T RA). Methods An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and nonpharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A?D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0?10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. Results Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4?9.6). Conclusions These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
arthritis
fibromyalgia
inflammation
rheumatoid
ultrasonography
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 1 (2022), p. 20-33. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) van der Goes, Marlies C. Kent, Alison Bakkers, Margôt Pchelnikova, Polina Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard van Riel, Piet Dumas, Sophie Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. van der Heijde, Désirée van Laar, Jacob M.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM088182
035-os BibID:(WOS)000607296800019 (Scopus)85098069546
Első szerző:Nagy György
Cím:EULAR definition of difficult-to-treat rheumatoid arthritis / György Nagy, Nadia M. T. Roodenrijs, Paco M. J. Welsing, Melinda Kedves, Attila Hamar, Marlies C. van der Goes, Alison Kent, Margot Bakkers, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest Choy, Maxime Dougados, Johannes W. G. Jacobs, Rinie Geenen, Hans W. J. Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Loriane Gutermann, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L. Hyrich, Ulf Mueller-Ladner, Maya H. Buch, Iain B. McInnes, Désirée van der Heijde, Jacob M. van Laar
Dátum:2021
ISSN:0003-4967
Megjegyzések:Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ?2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 80 : 1 (2021), p. 31-35. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) Goes, Marlies C. van der Kent, Alison Bakkers, Margôt Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard Riel, Piet van Gutermann, Loriane Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. Heijde, Désirée van der Laar, Jacob M. van
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM081587
Első szerző:Najm, Aurélie
Cím:EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases / Aurélie Najm, Elena Nikiphorou, Marie Kostine, Christophe Richez, John D. Pauling, Axel Finckh, Valentin Ritschl, Yeliz Prior, Petra Balázová, Simon Stones, Zoltan Szekanecz, Annamaria Iagnocco, Sofia Ramiro, Francisca Sivera, Maxime Dougados, Loreto Carmona, Gerd Burmester, Dieter Wiek, Laure Gossec, Francis Berenbaum
Dátum:2019
Megjegyzések:Background Mobile health applications (apps) are available to enable people with rheumatic and musculoskeletal diseases (RMDs) to better self-manage their health. However, guidance on the development and evaluation of such apps is lacking. Objectives The objective of this EULAR task force was to establish points to consider (PtC) for the development, evaluation and implementation of apps for self-management of RMDs. Methods A systematic literature review of app content and development strategies was conducted, followed by patient focus group and an online survey. Based on this information and along with task force expert opinion, PtC were formulated in a face-to-face meeting by a multidisciplinary task force panel of experts, including two patient research partners. The level of agreement among the panel in regard to each PtC was established by anonymous online voting. Results Three overarching principles and 10 PtC were formulated. Three PtC are related to patient safety, considered as a critical issue by the panel. Three are related to relevance of the content and functionalities. The requirement for transparency around app development and funding sources, along with involvement of relevant health professionals, were also raised. Ease of app access across ages and abilities was highlighted, in addition to considering the cost benefit of apps from the outset. The level of agreement was from 8.8 to 9.9 out of 10. Conclusion These EULAR PtC provide guidance on important aspects that should be considered for the development, evaluation and implementation of existing and new apps.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Rheumatic and Musculoskeletal Diseases. - 5 (2019), p. 1-7. -
További szerzők:Nikiphorou, Elena (reumatológus) Kostine, Marie Richez, Christophe Pauling, John D. Finckh, Axel Ritschl, Valentin Prior, Yeliz Balázová, Petra Stones, Simon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Iagnocco, Annamaria Ramiro, Sofia Sivera, Francisca Dougados, Maxime Carmona, Loreto Burmester, Gerd R. Wiek, Dieter Gossec, Laure Berenbaum, Francis
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM075277
035-os BibID:(WoS)000451780400011 (Scopus)85053158051
Első szerző:Roodenrijs, Nadia M. T.
Cím:Characteristics of difficult-to-treat rheumatoid arthritis : results of an international survey / Nadia M. T. Roodenrijs, Maria J. H. de Hair, Marlies C. van der Goes, Johannes W. G. Jacobs, Paco M. J. Welsing, Désirée van der Heijde, Daniel Aletaha, Maxime Dougados, Kimme L. Hyrich, Iain B. McInnes, Ulf Mueller-Ladner, Ladislav Senolt, Zoltan Szekanecz, Jacob M. van Laar, György Nagy, EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis
Dátum:2018
ISSN:0003-4967
Megjegyzések:Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite treatment according to current European League Against Rheumatism (EULAR) management recommendations. These focus on early phases of the disease and pharmacological management. We aimed to identify characteristics of difficult-to-treat RA and issues to be addressed in its workup and management that are not covered by current management recommendations. METHODS: An international survey was conducted among rheumatologists with multiple-choice questions on disease characteristics of difficult-to-treat RA. Using open questions, additional items to be addressed and items missing in current management recommendations were identified. RESULTS: 410 respondents completed the survey: 50% selected disease activity score assessing 28 joints >3.2 OR presence of signs suggestive of active disease as characteristics of difficult-to-treat RA; 42% selected fatigue; 48% selected failure to ?2 conventional synthetic disease-modifying antirheumatic drugs (DMARDs) AND ?2 biological/targeted synthetic DMARDs; 89% selected inability to taper glucocorticoids below 5 mg or 10 mg prednisone equivalent daily. Interfering comorbidities, extra-articular manifestations and polypharmacy were identified as important issues missing in current management recommendations. CONCLUSIONS: There is wide variation in concepts of difficult-to-treat RA. Several important issues regarding these patients are not addressed by current EULAR recommendations.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
disease activity
rheumatoid Arthritis
treatment
Megjelenés:Annals Of The Rheumatic Diseases. - 77 (2018), p. 1705-1709. -
További szerzők:Hair, Maria J. H. de Goes, Marlies C. van der Jacobs, Johannes W. G. Welsing, Paco M. J. Heijde, Désirée van der Aletaha, Daniel Dougados, Maxime Hyrich, Kimme L. McInnes, Iain B. Mueller-Ladner, Ulf Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Laar, Jacob M. van Nagy György EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.